{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:03:49Z","timestamp":1753891429357,"version":"3.41.2"},"reference-count":74,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T00:00:00Z","timestamp":1714608000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2024.1384002","type":"journal-article","created":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T04:59:08Z","timestamp":1714625948000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness of CAR-T treatment toward the potential risk of second malignancies"],"prefix":"10.3389","volume":"15","author":[{"given":"Massimo","family":"Martino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaetana","family":"Porto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgia","family":"Policastro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caterina","family":"Alati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Loteta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Caterina","family":"Mic\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clizia","family":"Argir\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Altomonte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiziana","family":"Moscato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Demetrio","family":"Labate","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo","family":"Dattola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmelo Massimiliano","family":"Rao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Cogliandro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filippo Antonio","family":"Canale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginia","family":"Naso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianfranco","family":"Filippelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonino","family":"Iaria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Pitea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,5,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1007\/s10529-023-03461-0","article-title":"Recentadvances and current challenges in CAR-T cell therapy","volume":"46","author":"Joy","year":"2024","journal-title":"Biotechnol Lett"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.5551","article-title":"(CAR-T) cells: Novelcell therapy for hematologicalmalignancies","volume":"12","author":"Abbasi","year":"2023","journal-title":"Cancer Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22042150","article-title":"Review of Clinical Outcomes of CAR T-Cell Therapies for B-Acute LymphoblasticLeukemia","volume":"22","author":"Martino","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24021045","article-title":"Do CAR-T and AllogeneicStem Cell TransplantBothHave a Place in LymphoidNeoplasms","volume":"24","author":"Martino","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2023.2292634","article-title":"Integrating CAR-T cell therapy into the management of DLBCL: whatwe are learning","volume":"23","author":"Martino","year":"2023","journal-title":"Expert OpinBiolTher"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.4084\/MJHID.2024.012","article-title":"CAR-T Cell Therapy for FollicularLymphomas","volume":"16","author":"Testa","year":"2024","journal-title":"Mediterr J HematolInfectDis"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16010046","article-title":"Chimeric Antigen Receptor-T Cell Therapy for Lymphoma: New Settings and Future Directions","volume":"16","author":"Benevolo Savelli","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13112639","article-title":"CART-Cell Therapy: Recent Advances and New Evidence in Multiple Myeloma","volume":"13","author":"Martino","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2021.1872540","article-title":"An update on B-cell maturation antigen-targeted therapies in Multiple Myeloma","volume":"21","author":"Martino","year":"2021","journal-title":"Expert Opin Biol Ther"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3343\/alm.2023.0388","article-title":"Current Challenges in Chimeric Antigen Receptor T-cell Therapy in Patients With B-cell Lymphoid Malignancies","volume":"44","author":"Kim","year":"2024","journal-title":"Ann Lab Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.annonc.2020.10.478","article-title":"Side-effect management of chimeric antigen receptor (CAR) T-cell therapy","volume":"32","author":"Schubert","year":"2021","journal-title":"Ann Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-015-2585-7","article-title":"Tumor lysis syndrome in the era of novel and targeted agents in patients with hematologic malignancies: a systematic review","volume":"95","author":"Howard","year":"2016","journal-title":"Ann Hematol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3109\/14653241003709686","article-title":"Adverse events following infusion of T cells for adoptive immunotherapy: a 10-year experience","volume":"12","author":"Cruz","year":"2010","journal-title":"Cytotherapy"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-384388","article-title":"B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells","volume":"119","author":"Kochenderfer","year":"2012","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1002\/hon.2302","article-title":"Incidence and epidemiology of non-Hodgkin lymphoma and risk of second malignancy among 22\u2009466 survivors in Israel with 30\u2009years of follow-up","volume":"35","author":"Tadmor","year":"2017","journal-title":"Hematol Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1259\/bjr.20180390","article-title":"Review of risk factors of secondary cancers among cancer survivors","volume":"92","author":"Demoor-Goldschmidt","year":"2019","journal-title":"Br J Radiol"},{"key":"B17","unstructured":""},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0615-5","article-title":"CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma: current status and perspectives","volume":"33","author":"Mohty","year":"2019","journal-title":"Leukemia"},{"key":"B21","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022018893","article-title":"Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma","volume":"141","author":"Neelapu","year":"2023","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","first-page":"4864","DOI":"10.1182\/blood-2023-174288","article-title":"Curative Potential of Axicabtagene Ciloleucel (Axi-Cel): An Exploratory Long-Term Survival Assessment in Patients with Refractory Large B-Cell Lymphoma from ZUMA-1","volume":"142","author":"Neelapu","year":"2023","journal-title":"Blood"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00375-2","article-title":"Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Schuster","year":"2021","journal-title":"Lancet Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023020854","article-title":"Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001","volume":"143","author":"Abramson","year":"2023","journal-title":"Blood"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-148039","article-title":"Primary analysis of ZUMA\u22127: a phase 3 randomized trial of axicabtagene ciloleucel (Axi-Cel) versus standard\u2212of\u2212care therapy in patients with relapsed\/refractory large B-cell lymphoma","volume":"138","author":"Locke","year":"2021","journal-title":"Blood"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-147913","article-title":"Lisocabtagene maraleucel (liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, versus standard of care (SOC) with salvage chemotherapy (CT) followed by autologous stem cell transplantation (ASCT) as second-line (2L) treatment in patients (Pts) with relapsed or refractory (R\/R) large B-cell lymphoma (LBCL): results from the randomized phase 3 transform study","volume":"138","author":"Kamdar","year":"2021","journal-title":"Blood"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N Engl J Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-3136","article-title":"Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed\/Refractory Large B-Cell Lymphoma","volume":"29","author":"Westin","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1182\/blood-2023-173873","article-title":"Improved Overall Survival with AxicabtageneCiloleucel Vs Standard of Care in Second-Line Large B-Cell LymphomaAmong the Elderly: A Subgroup Analysis of ZUMA-7","volume":"142","author":"Kersten","year":"2023","journal-title":"Blood"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01731-4","article-title":"Axicabtageneciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial","volume":"28","author":"Neelapu","year":"2022","journal-title":"NatMed"},{"key":"B35","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1182\/blood-2023-174510","article-title":"3-Year Analysis of ZUMA-12: A Phase 2 Study of AxicabtageneCiloleucel (Axi-Cel) As First-Line Therapy in Patients with High-Risk Large B-Cell Lymphoma (LBCL)","volume":"142","author":"Chavez","year":"2023","journal-title":"Blood"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-022-01691-w","article-title":"Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022","volume":"57","author":"Snowden","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"B37","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1182\/blood-2023-180242","article-title":"Multicenter, Real-World Study in Patients with R\/R Large B-Cell Lymphoma (LBCL) Who Received Lisocabtagene Maraleucel (liso-cel) in the United States (US)","volume":"142","author":"Crombie","year":"2023","journal-title":"Blood"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-11-817775","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djw257","article-title":"Beyond RCHOP: A Blueprint for Diffuse Large B Cell Lymphoma Research","volume":"108","author":"Nowakowski","year":"2016","journal-title":"J Natl Cancer Inst"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00339-4","article-title":"Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study","volume":"23","author":"Sehgal","year":"2022","journal-title":"Lancet Oncol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1182\/blood-2023-180952","article-title":"Lisocabtagene Maraleucelas Second-Line Therapy for R\/R Large B-Cell Lymphoma in Patients Not Intended for Hematopoietic Stem Cell Transplant: Final Analysis of the Phase 2 PILOT Study","volume":"142","author":"Sehgal","year":"2023","journal-title":"Blood"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02826-w","article-title":"T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy","volume":"30","author":"Ghilardi","year":"2024","journal-title":"Nat Med"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01622-0","article-title":"Tisagenlecleucel in adultrelapsed or refractoryfollicularlymphoma: the phase 2 ELARA trial","volume":"28","author":"Fowler","year":"2022","journal-title":"NatMed"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(21)01911-X","article-title":"IBCL-195: Primaryanalysis of the phase 2 ELARA trial: Tisagenlecleucelefficacy and safety in adultpatients with relapsed\/refractoryfollicularlymphoma (r\/r FL)","volume":"21","author":"Schuster","year":"2021","journal-title":"ClinLymphomaMyelomaLeuk"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023021567","article-title":"Durable Response After Tisagenlecleucel in Adults With Relapsed\/Refractory Follicular Lymphoma: ELARA Trial Update","author":"Dreyling","year":"2024","journal-title":"Blood"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.7515","article-title":"Outcomes in ZUMA-5 with axicabtagene ciloleucel (axi-cel) in patients (pts) with relapsed\/refractory (R\/R) indolent non-Hodgkin lymphoma (iNHL) who had the high-risk feature of progression within 24 months from initiation of first anti-CD20\u2013containing chemoimmunotherapy (POD24)","volume":"39","author":"Jacobson","year":"2021","journal-title":"J Clin Oncol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial","volume":"23","author":"Jacobson","year":"2022","journal-title":"Lancet Oncol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02370","article-title":"Three-Year Follow-Up of KTE-X19 in Patients With Relapsed\/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study","volume":"41","author":"Wang","year":"2023","journal-title":"J Clin Oncol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1182\/blood-2023-174273","article-title":"Outcomes of Patients with Relapsed\/Refractory Mantle Cell Lymphoma Treated with BrexucabtageneAutoleucel in ZUMA-2 and ZUMA-18, an Expanded Access Study","volume":"142","author":"Goy","year":"2023","journal-title":"Blood"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2022-1317","article-title":"Cilta-cel, a BCMA-targeting CAR-T therapy for heavily pretreated patients with relapsed\/refractory multiple myeloma","volume":"19","author":"Martin","year":"2023","journal-title":"Future Oncol"},{"key":"B51","unstructured":"ABECMA\u00ae (idecabtagene vicleucel) prescribing information)"},{"key":"B52","unstructured":"ABECMA\u00ae (idecabtagene vicleucel) Summary of Product Characteristics)"},{"key":"B53","doi-asserted-by":"publisher","first-page":"8016","DOI":"10.1200\/JCO.2021.39.15_suppl.8016","article-title":"Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T therapy, in relapsed and refractory multiple myeloma: updated KarMMa results","volume":"39","author":"Anderson","year":"2021","journal-title":"J Clin Oncol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N Engl J Med"},{"key":"B55","unstructured":"CARVYKTI\u00ae (ciltacabtagene autoleucel) prescribing information)"},{"key":"B56","unstructured":"CARVYKTI\u00ae (ciltacabtagene autoleucel) Summary of Product Characteristics)"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00842","article-title":"Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2 years follow-up","volume":"41","author":"Martin","year":"2023","journal-title":"J Clin Oncol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s13045-022-01301-8","article-title":"Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase I, single-arm, open-label, multicenter study in China (LEGEND-2)","volume":"15","author":"Zhao","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200301163480314","article-title":"A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency","volume":"348","author":"Hacein-Bey-Abina","year":"2003","journal-title":"N Engl J Med"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-03-340711","article-title":"Ubiquitous high-level gene expression in hematopoietic lineages provides effective lentiviral gene therapy of murine Wiskott-Aldrich syndrome","volume":"119","author":"Astrakhan","year":"2012","journal-title":"Blood"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1172\/JCI31661","article-title":"Gammaretrovirus-mediated correction of SCID-X1 is associated with skewed vector integration site distribution in vivo","volume":"117","author":"Schwarzwaelder","year":"2007","journal-title":"Clin Invest"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.09.008","article-title":"Absence of Replication-Competent Lentivirus in the Clinic: Analysis of Infused T Cell Products","volume":"26","author":"Cornetta","year":"2018","journal-title":"Mol Ther"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007423","article-title":"Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells","volume":"7","author":"Lamble","year":"2023","journal-title":"Blood Adv"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.12.023","article-title":"CAR19 Therapy Drives Expansion of Clonal Hematopoiesis and Associated Cytopenias","volume":"30","author":"Hamilton","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02767-w","article-title":"Unanswered questions following reports of secondary malignancies after CAR-T cell therapy","volume":"30","author":"Levine","year":"2024","journal-title":"Nat Med"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.1920","article-title":"Second neoplasms in survivors of childhood cancer: findings from the Childhood Cancer Survivor Study cohort","volume":"27","author":"Meadows","year":"2009","journal-title":"J Clin Oncol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.158","article-title":"Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin's lymphoma","volume":"23","author":"Brown","year":"2005","journal-title":"J Clin Oncol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.34.8268","article-title":"Second cancer risk after chemotherapy for Hodgkin\u2019s lymphoma: a collaborative British cohort study","volume":"29","author":"Swerdlow","year":"2011","journal-title":"J Clin Oncol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1002\/mpo.1126","article-title":"Therapy-related leukemia associated with alkylating agents","volume":"36","author":"Davies","year":"2001","journal-title":"Med Pediatr Oncol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.14694\/EdBook_AM.2014.34.e57","article-title":"The rising incidence of second cancers: patterns of occurrence and identification of risk factors for children and adults","volume":"34","author":"Morton","year":"2014","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-09-1156","article-title":"Long-term mortality from second malignant neoplasms in 5-year survivors of solid childhood tumors: temporal pattern of risk according to type of treatment","volume":"19","author":"Tukenova","year":"2010","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1667\/RR14453.1","article-title":"Stomach cancer following hodgkin lymphoma, testicular cancer and cervical cancer: a pooled analysis of three international studies with a focus on radiation effects","volume":"187","author":"Gilbert","year":"2017","journal-title":"Radiat Res"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1097\/MOH.0b013e3281900f01","article-title":"Insertional mutagenesis in gene therapy and stem cell biology","volume":"14","author":"Baum","year":"2007","journal-title":"Curr Opin Hematol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1615\/CritRevEukaryotGeneExpr.2019026820","article-title":"Review: Oncogenic Insertional Mutagenesis as a Consequence of Retroviral Gene Therapy for X-Linked Severe Combined Immunodeficiency Disease","volume":"29","author":"Ahmed","year":"2019","journal-title":"Crit Rev Eukaryot Gene Expr"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1384002\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T04:59:10Z","timestamp":1714625950000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1384002\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,2]]},"references-count":74,"alternative-id":["10.3389\/fimmu.2024.1384002"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1384002","relation":{},"ISSN":["1664-3224"],"issn-type":[{"type":"electronic","value":"1664-3224"}],"subject":[],"published":{"date-parts":[[2024,5,2]]},"article-number":"1384002"}}